Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
TNXP's Cash-to-Debt is ranked higher than
94% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. TNXP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TNXP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: No Debt Max: No Debt
Current: No Debt
0.02
No Debt
Interest Coverage No Debt
TNXP's Interest Coverage is ranked higher than
87% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TNXP: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TNXP' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -5.40
WACC vs ROIC
19.95%
3882.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -89.92
TNXP's ROE % is ranked lower than
79% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. TNXP: -89.92 )
Ranked among companies with meaningful ROE % only.
TNXP' s ROE % Range Over the Past 10 Years
Min: -291.37  Med: -118.38 Max: -48.84
Current: -89.92
-291.37
-48.84
ROA % -83.39
TNXP's ROA % is ranked lower than
78% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. TNXP: -83.39 )
Ranked among companies with meaningful ROA % only.
TNXP' s ROA % Range Over the Past 10 Years
Min: -1993.91  Med: -112.72 Max: -45.65
Current: -83.39
-1993.91
-45.65
ROC (Joel Greenblatt) % -22253.36
TNXP's ROC (Joel Greenblatt) % is ranked lower than
83% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. TNXP: -22253.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TNXP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23669.57  Med: -15208.28 Max: -11651.72
Current: -22253.36
-23669.57
-11651.72
3-Year EBITDA Growth Rate 51.30
TNXP's 3-Year EBITDA Growth Rate is ranked higher than
74% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. TNXP: 51.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TNXP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -228.8  Med: 4.2 Max: 51.3
Current: 51.3
-228.8
51.3
3-Year EPS without NRI Growth Rate 51.40
TNXP's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. TNXP: 51.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TNXP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -203.3  Med: 5.1 Max: 51.4
Current: 51.4
-203.3
51.4
GuruFocus has detected 2 Warning Signs with Tonix Pharmaceuticals Holding Corp TNXP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TNXP's 30-Y Financials

Financials (Next Earnings Date: 2018-08-14)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

TNXP Guru Trades in Q2 2017

Jim Simons Sold Out
» More
Q3 2017

TNXP Guru Trades in Q3 2017

Jim Simons 39,200 sh (New)
» More
Q4 2017

TNXP Guru Trades in Q4 2017

Jim Simons 74,800 sh (+90.82%)
» More
Q1 2018

TNXP Guru Trades in Q1 2018

Jim Simons 108,000 sh (+44.39%)
» More
» Details

Insider Trades

Latest Guru Trades with TNXP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Tonix Pharmaceuticals Holding Corp does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:LSE:N4P, HKSE:08019, BOM:533543, OTCPK:INNV, ROCO:4102, TSE:4556, DHA:CENTRALPHL, XSAT:RESP, BOM:524758, TSXV:VIV, LSE:SAR, ASX:VLS, BOM:524075, NAS:PRPH, XTER:SAC, BOM:524500, OSL:NAVA, ASX:IDT, OSTO:NVP, BOM:500009 » details
Traded in other countries:TPMN.Germany,
Headquarter Location:USA
Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company dedicated to the development of pharmaceutical products to address public health challenges. Its drug development program is focused on delivering treatment for PTSD.

Tonix Pharmaceuticals Holding Corp is a clinical-stage pharmaceutical company. The company is focused on delivering an efficacious and safe long-term treatment for PTSD. PTSD is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its product candidate, TNX-102 SL, a proprietary low-dose cyclobenzaprine sublingual tablet, designed for bedtime administration, is in Phase 3 development as a potential treatment for PTSD.

Top Ranked Articles about Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD

Ratios

vs
industry
vs
history
PB Ratio 1.77
TNXP's PB Ratio is ranked higher than
91% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. TNXP: 1.77 )
Ranked among companies with meaningful PB Ratio only.
TNXP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.04
Current: 1.77
0
2.04
EV-to-EBIT -0.70
TNXP's EV-to-EBIT is ranked higher than
100% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. TNXP: -0.70 )
Ranked among companies with meaningful EV-to-EBIT only.
TNXP' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.93  Med: 0 Max: 0.52
Current: -0.7
-0.93
0.52
EV-to-EBITDA -0.70
TNXP's EV-to-EBITDA is ranked higher than
100% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. TNXP: -0.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
TNXP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.93  Med: 0 Max: 0.52
Current: -0.7
-0.93
0.52
Current Ratio 8.75
TNXP's Current Ratio is ranked higher than
97% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. TNXP: 8.75 )
Ranked among companies with meaningful Current Ratio only.
TNXP' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 8.39 Max: 22.02
Current: 8.75
0.05
22.02
Quick Ratio 8.75
TNXP's Quick Ratio is ranked higher than
97% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. TNXP: 8.75 )
Ranked among companies with meaningful Quick Ratio only.
TNXP' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 8.39 Max: 22.02
Current: 8.75
0.05
22.02

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -93.50
TNXP's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. TNXP: -93.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TNXP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -168.4  Med: -97.6 Max: -89.1
Current: -93.5
-168.4
-89.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.97
TNXP's Price-to-Net-Cash is ranked higher than
99% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. TNXP: 1.97 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TNXP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.77  Med: 1.86 Max: 64.52
Current: 1.97
0.77
64.52
Price-to-Net-Current-Asset-Value 1.81
TNXP's Price-to-Net-Current-Asset-Value is ranked higher than
98% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. TNXP: 1.81 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TNXP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.74  Med: 1.77 Max: 56.5
Current: 1.81
0.74
56.5
Price-to-Tangible-Book 1.80
TNXP's Price-to-Tangible-Book is ranked higher than
92% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. TNXP: 1.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TNXP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.73  Med: 1.75 Max: 47.55
Current: 1.8
0.73
47.55
Earnings Yield (Greenblatt) % -146.39
TNXP's Earnings Yield (Greenblatt) % is ranked higher than
100% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. TNXP: -146.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TNXP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -494998.23  Med: 0 Max: 221999.14
Current: -146.39
-494998.23
221999.14

More Statistics

EPS (TTM) $ -2.98
Beta2.85
Volatility52.27%
52-Week Range $2.70 - 5.11
Shares Outstanding (Mil)8.46

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -2.50 -0.95 -0.85
EPS without NRI ($) -2.50 -0.95 -0.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}